Nicolas Hoertel, MD, MPH, PhD
@HoertelN
Followers
1K
Following
423
Media
4
Statuses
269
MCU-PH à Université de Paris, INSERM, GHU APHP.Centre, Hôpital Corentin-Celton MD, MPH, PhD (Assoc. Prof.) in Psychiatry/Neurosciences Opinions are my own
Issy-les-Moulineaux, France
Joined August 2021
Pour les risques de l’hydroxychloroquine (qui n’est pas recommandée dans le traitement de la COVID-19) pendant la grossesse, lire : https://t.co/zEqMU4pDuG
#Mediapart
14
21
53
Enquête sur la piste négligée des antidépresseurs pour traiter le Covid. Un feuilleton en cinq épisodes publié cette semaine dans @FactuelOff
https://t.co/qmc5Wnn9Ij
30
108
215
13/ Should we use PAX in 🏥 for hi-risk inpts who may progress❓While effective for OP, there is limited IP data and many pts w/ contraindications (medical cond’ns or meds)❗️ 🔸Paris cohort study, 62,525 pts 🔸14.6% (9136) had contraindications 🔸Older pts 27% vs younger pts 9%
1
1
2
🆕️⚡️Systematic review & meta-analysis #JAC 9 RCTs ~ 30K In a predominantly immunized population of COVID-19 outpatients, molnupiravir has no effect on mortality, probably none on ‘hospitalization or death’ and effects on symptom resolution are uncertain
academic.oup.com
AbstractBackground. The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is unclear.Methods. We conducted a systematic review until 1
0
9
25
This result from high-quality #RCT confirms prior #efficacy data of #fluvoxamine in #Covid, including several independent RCTs that have evaluated #fluvoxamine at this exact medium #dose, multiple interventional cohort studies and a high number of observational studies.
1
1
4
🔥 Large RCT demonstrates that treatment with oral #fuvoxamine (100 mg twice a day for 10 days) plus inhaled #budesonide among high-risk VACCINATED outpatients with COVID-19 is safe and significantly and importantly reduces the risk of severe disease. https://t.co/zbxbqJFFge
acpjournals.org
Background: Previous trials have demonstrated the effects of fluvoxamine alone and inhaled budesonide alone for prevention of disease progression among outpatients with COVID-19. Objective: To...
1
2
12
New retrospective cohort study of 116,498 individuals with #COVID-19: #antidepressant use among individuals with a psychiatric disorder is associated with reduced risk of #sepsis (p=0.033) and #death (p=0.026), confirming multiple prior cohort studies. https://t.co/RKy5hCZgBh
2
13
27
#Borderline personality disorder may be the psychobehavioral expression of a broader #coping strategy whereby individuals deal with early life #adversity by prioritizing immediate #reproductive goals over long-term somatic maintenance ones. https://t.co/NnqYrVQriq
jamanetwork.com
This cross-sectional study examines whether the emergence of borderline personality disorder is associated with the prioritization of immediate reproductive goals over longer-term somatic maintenance...
0
0
3
👍 paper @montastrucf Compared to AEs recorded in https://t.co/2w6HLPABal, 41.5% of serious AEs and 39% of non-serious AEs were not reported in the papers. The majority = psychiatric events + cardiovascular events. 94% of those = from esketamine groups.
1
15
25
🔥 Latest systematic review and meta-analysis on #fluvoxamine and #Covid-19 ➡️ Fluvoxamine 100 mg bid is well tolerated and significantly associated with ⬇️ #mortality, #hospitalization, and composite of hospitalization/ER visits, but not at lower dose. https://t.co/M7ZHWVASTL
5
32
85
🔥 TOGETHER RCT 🔥 Treatment with oral fluvoxamine plus inhaled budesonide among high-risk outpatients with early COVID-19 reduced the incidence of severe disease requiring advanced care #IDTwitter
https://t.co/S91Ao0kBlD
6
24
71
Impact of lithium on mortality among #olderadults with major #psychiatric disorders: A 5-year prospective multicenter study https://t.co/Hkp6phtENn
@HoertelN
tandfonline.com
Prior studies report conflicting results about the association between lithium use and all-cause mortality. In addition, data are scarce on this association among older adults with psychiatric diso...
0
1
1
American Journal of Therapeutics 2023 LETTERS TO THE EDITOR Antidepressants Are Associated With a Reduction in the Risk of Death in #COVID-19 Disease Patients. #Science
#COVID19
#research
#fluvoxamine
https://t.co/AJ0UrTRCsq
0
4
6
Congratulations to Pr @brucekirenga and all his colleagues from @Makerere @MakerereHosp for performing this important study. I was honored to cooperate with this fantastic team (@julienpotet: thanks!)
0
0
5
⚠️ New prospective cohort study of COVID-19 adult inpatients in Uganda ➡️ #fluvoxamine 100 mg * 2 per day for 10 days significantly reduces mortality by 68% (AHR = 0.32; NNT= 4.5), increases rates of complete symptom resolution, and is well tolerated https://t.co/UyZgUiFRoR
nature.com
Molecular Psychiatry - Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study
6
11
23
⚠️ New large retrospective cohort study of #COVID-19 inpatients from Hong Kong during the Omicron period ➡️#FIASMA #antidepressants, specifically #fluoxetine, significantly associated with ⬇️ICU admission and ⬇️mortality, in both un/vaccinated people https://t.co/gdV5Vm3zyM
thelancet.com
Antidepressant use was associated with a lower risk of severe COVID-19. The findings support the continuation of antidepressants in patients with COVID-19, and provide evidence for the treatment...
2
6
25
"Une enquête de @SantePubliqueFr a montré une hausse des épisodes de #dépression en 2021 dans toute la population ; Avec 1 #jeune sur 5 présentant des troubles dépressifs, la part des 18-24 ans touchés a quasiment doublé depuis 2017" | @pascale_santi
https://t.co/lXJY0oVL1B
lemonde.fr
Une enquête de Santé publique France a montré une hausse des épisodes de dépression en 2021 dans toute la population ; la part des 18-24 ans touchés a quasiment doublé depuis 2017.
6
49
74
🔥 Latest systematic review and meta-analysis on #fluvoxamine and #Covid-19 ➡️ Fluvoxamine 100 mg bid is well tolerated and significantly associated with ⬇️ #mortality, #hospitalization, and composite of hospitalization/ER visits, but not at lower dose. https://t.co/M7ZHWVASTL
5
32
85